Every 10-Q that Ironwood Pharmaceuticals, Inc. (IRWD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IRWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRWD filings page.
Ironwood Pharmaceuticals, Inc. reported total revenues of $113,041 thousand for the quarter ended June 30, 2026, up from $85,239 thousand a year earlier, driven almost entirely by collaborative arrangements revenue. Net income rose to $51,291 thousand from $23,599 thousand. For the first six months of 2026, revenues were $219,547 thousand and net income was $92,064 thousand, compared with revenues of $126,382 thousand and a net loss of $13,787 thousand in 2025.
Cash and cash equivalents were $79,127 thousand at June 30, 2026. Net cash provided by operating activities increased to $63,397 thousand for the six-month period. Ironwood repaid $200,000 thousand of 1.50% convertible senior notes at maturity in June 2026 and had $385,000 thousand outstanding under its revolving credit facility. Total liabilities were $446,971 thousand and stockholders’ deficit narrowed to $161,843 thousand.
The company continues to commercialize LINZESS globally through partners including AbbVie, Astellas and Grand Life Sciences and to earn royalties on CONSTELLA. It is advancing apraglutide for short bowel syndrome with intestinal failure, having initiated the STARS-2 confirmatory Phase III trial in June 2026 while continuing the STARS Extend open-label study.
Ironwood Pharmaceuticals reported a sharp turnaround to profitability for the quarter ended March 31, 2026. Total revenues rose to $106.5 million from $41.1 million a year earlier, driven mainly by higher collaborative arrangements revenue from LINZESS in the U.S. and abroad.
Net income reached $40.8 million versus a net loss of $37.4 million in the prior-year quarter, with diluted earnings per share improving to $0.24 from a loss of $0.23. Operating income was $72.6 million compared with a loss of $29.1 million, reflecting higher revenue and lower research and development, selling, general and administrative, and restructuring costs.
Ironwood ended the quarter with $220.5 million in cash and cash equivalents. Liabilities included a $200.0 million tranche of 1.50% convertible senior notes due 2026 and $385.0 million outstanding under a revolving credit facility, contributing to a stockholders’ deficit of $217.1 million. The company continues to focus on LINZESS commercialization and advancing apraglutide through late-stage clinical development for short bowel syndrome with intestinal failure.
Ironwood Pharmaceuticals (IRWD) reported stronger Q3 2025 results. Total revenues were $122.1 million, up from $91.6 million a year ago, driven mainly by collaborative revenue from the LINZESS partnership with AbbVie in North America ($120.5 million). Operating income rose to $75.5 million from $25.6 million, and net income improved to $40.1 million versus $3.6 million, with diluted EPS of $0.23.
Expenses declined year over year, with research and development at $22.5 million and selling, general and administrative at $21.9 million; restructuring expense was $2.2 million. Cash and cash equivalents increased to $140.4 million, supported by $52.5 million net cash from operating activities for the nine-month period. The company reported a current portion of convertible senior notes of $199.5 million and $385.0 million outstanding on its revolving credit facility. As of October 31, 2025, 162,678,647 Class A shares were outstanding.
For the first nine months of 2025, revenues were $248.4 million and net income was $26.3 million, reflecting improved profitability compared to the prior-year period.
Ironwood Pharmaceuticals reported a profitable quarter but a loss for the first half of 2025. For the three months ended June 30, 2025 the company recorded $23.6 million of net income (basic EPS $0.15), driven by collaborative arrangements revenue of $85.2 million and reduced operating costs. For the six months ended June 30, 2025, revenue from collaborative arrangements was $126.4 million versus $169.3 million a year earlier, and the company recorded a $13.8 million net loss for the period.
The balance sheet shows $92.9 million of cash and cash equivalents and accounts receivable of $86.2 million, largely due from AbbVie. Current liabilities increased sharply to $232.5 million primarily because the $200.0 million 2026 Convertible Notes are presented, in part, as a current obligation (net carrying amount $199.3 million) and these notes mature on June 15, 2026. Management states available liquidity and borrowing capacity are sufficient to meet operations for at least the next 12 months.